Could starting MS treatment within two weeks change the course of the disease?

NCT ID NCT05418010

Recruiting now Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 25 times

Summary

This study tests whether giving the drug natalizumab (Tyruko®) within 14 days of first MS symptoms can help repair nerve damage better than a placebo. It involves 40 adults aged 18-55 who have had a first episode of demyelination (suggestive of MS) and show at least two brain lesions on MRI. The goal is to see if very early, strong treatment can improve long-term outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Royal London Hospital
NOT_YET_RECRUITING

London, E1 1FR, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••
St George's Hospital
RECRUITING

London, SW17 0QT, United Kingdom

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CLINICALLY ISOLATED SYNDROME OF DEMYELINATION CLINICALLY ISOLATED SYNDROME OF DEMYELINATION MULTIPLE SCLEROSIS